DARC Diagnostic Test for Tumor Immunotherapy

Lead Inventor:

Melissa Davis, Ph.D.
Assistant Professor of Cell and Developmental Biology in Surgery, Weill Cornell Medical College
Scientific Director of the International Center for the Study of Breast Cancer Subtypes

Business Development Contact:
Brian Kelly
Director, Technology Licensing
(646) 962-7041
bjk44@cornell.edu
### Background & Unmet Need

- The Duffy Antigen Receptor for Chemokines (DARC), also known as Atypical Chemokine Receptor 1 (ACKR1), plays a major role in the regulation of circulating pro-inflammatory chemokines.
- A mutation in the DARC/ACKR1 gene, rs2814778, results in a Duffy-null allele.
- African American (AA) cohorts have over 70% allele frequency of this allele, and it is well known that pre-menopausal AA women have higher incident rates of breast cancer.
- However, the impact of DARC expression on treatment outcomes is unknown.

**Unmet Need:** Improved understanding of the role of DARC expression to guide treatment decisions.

### Technology Overview

- **The Technology:** Method for measuring DARC expression levels as a prognostic indicator of a patient’s response to tumor immunotherapy.
- **The Discovery:** Breast cancer patients with DARC-high tumors had significantly longer overall survival (OS) and relapse-free survival (RFS) compared to patients with DARC-low tumors.
- DARC-high tumors were also found to have significantly higher levels of the chemokine CCL2 but significantly lower levels of the chemokine CXCL8.
- Tumor immune cell populations were also found to be directly correlated to DARC expression, in all intrinsic tumor subtypes.
- Patients with DARC-high tumors may be more responsive to immunotherapies (e.g., checkpoint inhibitors), whereas patients with DARC-low tumors may benefit from chemotherapy, radiation therapy, and surgery.

### Inventors:
Melissa Davis

### Patents:
- US Application Filed
- EP Application Filed

### Publications:

### Biz Dev Contact:
Brian Kelly
(646) 962-7041
bjk44@cornell.edu

### Cornell Reference:
D-8495
DARC Diagnostic Test for Tumor Immunotherapy

Technology Applications

- Prognostic indicator of patient response to immunotherapies
- Predictor of long-term patient outcomes

Technology Advantages

- Strong correlation between DARC expression and breast cancer survival
- Test may be performed either through genetic testing or direct measurement of DARC protein levels
- Potential to be applied to additional tumor types beyond breast cancer

Supporting Data / Figures

![Graphs showing correlation and survival outcomes](image)

Figure 1: DARC expression is positively correlated with CCL2 and negatively correlated with CXCL8 expression. DARC expression is also significantly associated with improved survival.

Inventors: Melissa Davis

Patents:
- US Application Filed
- EP Application Filed

Publications:

Biz Dev Contact:
- Brian Kelly
  - (646) 962-7041
  - bjk44@cornell.edu

Cornell Reference:
- D-8495